Clinical Trial Update: Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial is assessing whether the nutritional supplement sulforaphane can protect against doxorubicin-related cardiotoxicity in breast c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anthracycline-induced Cardiotoxicity
• Breast Cancer

Drugs mentioned

• Sulforaphane (sulforaphane)

Snippet

Sponsor: Texas Tech University Health Sciences Center | Conditions: Anthracycline Related Cardiotoxicity in Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING